home / stock / ntec / ntec news

NTEC News and Press, Intec Pharma Ltd. From 03/15/23

Stock Information
Company Name: Intec Pharma Ltd.
Stock Symbol: NTEC
Market: NASDAQ
Menu
NTEC NTEC Quote NTEC Short NTEC News NTEC Articles NTEC Message Board
Get NTEC Alerts

News, Short Squeeze, Breakout and More Instantly...
NTEC - Indaptus Therapeutics to Present Poster on Its Decoy Anti-Tumor Platform at the American Association for Cancer Research Conference 2023

NEW YORK, March 15, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP, “Indaptus” or “the Company”), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announces that the American Association f...
NTEC - Indaptus Therapeutics Activates Emory Winship Cancer Institute as Trial Site in INDP-D101, Its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors

NEW YORK, March 13, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP, “Indaptus” or “the Company”), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announces that Atlanta, Ga.-based Emory W...

NTEC - Indaptus Therapeutics Doses First Subject in its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors

NEW YORK, March 07, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP, “Indaptus” or “the Company”), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announces the dosing of the first subject...

NTEC - Indaptus Therapeutics Names Robert Martell, M.D., Ph.D. to its Board of Directors

NEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP, “Indaptus” or “the Company”), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announces it has named Robert Martell, M.D...
NTEC - Indaptus Therapeutics Activates Morristown Medical Center as Trial Site in INDP-D101, Its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors

NEW YORK, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP, “Indaptus” or “the Company”), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announces the addition of Morristown Medic...

NTEC - Intec Closes Merger with Decoy Biosystems

Intec Closes Merger with Decoy Biosystems Completes $30 Million Private Placement Changes Corporate Name to Indaptus Therapeutics to Reflect Clinical Focus PR Newswire NEW YORK , Aug. 3, 2021 /PRNewswire/ -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("In...

NTEC - Intec Announces Expected Closing Date of Decoy Merger

Intec Announces Expected Closing Date of Decoy Merger PR Newswire JERUSALEM , Aug. 3, 2021 /PRNewswire/ -- Intec Parent , Inc. (NASDAQ: NTEC) (" Intec Parent " or the "Company"), today announced that the pending and previously announced reverse merger (th...
NTEC - MRIN, BLIN, BAP among mid-day movers

Gainers: ERYTECH Pharma (NASDAQ:ERYP) +64%. Allied Healthcare Products (NASDAQ:AHPI) +49%. iFresh (NASDAQ:IFMK) +35%. Marin Software Incorporated (NASDAQ:MRIN) +29%. Atlassian Corporation (NASDAQ:TEAM) +24%. Xiaobai Maimai (NASDAQ:HX) +18%. First High-School Education (NYSE:FHS) +16%. Bridgel...

NTEC - ERYTECH Pharma, Allied Healthcare Products leads healthcare gainers; Intec Pharma, Translate Bio among major losers

Gainers: ERYTECH Pharma (NASDAQ:ERYP) +84%, Allied Healthcare Products (NASDAQ:AHPI) +31%, SCWorx (NASDAQ:WORX) +18%, Veracyte (NASDAQ:VCYT) +13%, Misonix (NASDAQ:MSON) +11%. Losers: Intec Pharma (NASDAQ:NTEC) -20%, Translate Bio (NASDAQ:TBIO) ...

NTEC - Amazon, DiDi Global, Pinterest among premarket losers' pack

Pinterest (NYSE:PINS) -20% on Q2 earnings release Cassava Sciences (NASDAQ:SAVA) -17% despite presenting 'positive' data on simufilam for Alzheimer's 360 DigiTech (NASDAQ:QFIN) -12%. Annovis Bio (NYSE:ANVS) -11%. Uxin (NASDAQ:UXIN) -11% on Q4 earnings release. Le...
Previous 10 Next 10